ISTRADEFYLLINE CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE
Movement Disorders [2013] Mar 11 [Epub ahead of print] (Y.Mizuno, T.Kondo, the Japanese Istradefylline Study Group.
Researchers evaluated the efficacy and safety of istradefylline, which is being developed for the treatment of Parkinson's Disease. Istradefylline is an A(2A) adenosine receptor antagonist and so does not act by directly increasing the activity of dopamine. It is administered with L-dopa.
Researchers evaluated the efficacy and safety of istradefylline, which is being developed for the treatment of Parkinson's Disease. Istradefylline is an A(2A) adenosine receptor antagonist and so does not act by directly increasing the activity of dopamine. It is administered with L-dopa.
After a 12 week clinical trial using 20mg or 40mg istradefylline the change in daily OFF time was significantly reduced with 20mg per day and 40 mg per day. The daily OFF time was over 40 minutes less. However, the most common adverse event was dyskinesia, which occurred more commonly when taking istradefylline than when taking a placebo
No comments:
Post a Comment